Concerns surrounding the EU’s COVID-19 vaccination campaign refuse to die down. With AstraZeneca now reporting a safety scare – after already acknowledging supply constraints, export…
Since our last Teaser in November 2019, it has been a roller-coaster ride for Sanofi. While an impressive mid-term growth strategy and robust Q4-19 results…
We looked at stocks that stood in the best decile of performers both last week to 08/01/2021 inclusive and last month. This could be called…
Tesla makes the news with its all-time high and rising, up to its inclusion in the S&P500 by mid-December. But, over the last month, its…
It immediately appeared that the BioNTech(licensed by Pfizer) vaccine news of last week would trigger a logistics challenge of gargantuan proportions. As a reminder, usual…
BCP has been one the worst performers among our banks’ universe year-to-date. At -60%, the stock has managed to double the sector’s correction. This could…
As part of an indiscriminate sell-off, CaixaBank’s share price moved in tandem with the rest of the sector until the summer, when it started to overperform…
The mood music stopped about six months ago on a pre-COVID-19 high (19/02). It pays to group stocks into: a) those which, six months later,…
With central banks’ liquidity guns in action over the last three months, it is worth checking the successful long-short trades. This is obviously ex post work but…
AlphaValue’s Buy & Hold Portfolio continues to surprise on the positive side. The ytd outperformance is 15% so that it is down only 2% in…